Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 435.00
Bid: 430.00
Ask: 440.00
Change: 2.50 (0.58%)
Spread: 10.00 (2.326%)
Open: 432.50
High: 435.00
Low: 430.00
Prev. Close: 432.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

4 Apr 2008 07:01

Tristel PLC04 April 2008 Tristel plc ("Tristel" or "the Company") Director Share Purchase Tristel plc, the AIM listed provider of infection and contamination controlproducts, announces that on the 3rd April 2008 Peter Stephens, Chairman of theRemuneration Committee and Non-Executive Director, purchased 25,000 OrdinaryShares in the Company at 39 pence per share. Following the above purchase Mr Stephens has an interest in 1,085,681 OrdinaryShares in the Company, representing 4.04% the Company's issued share capital. Contacts: Tristel plcPaul Swinney, Chief Executive Tel: 01638 721 500 Daniel Stewart & Company PlcGraham Webster Tel: 020 7776 6576 Parkgreen Communications Ltd Tel: 020 7851 7480Lucy Lake Mob: 07894 263 046 lucy.lake@parkgreenmedia.com Notes to Editors Tristel's core business is the marketing of its proprietary chlorine dioxidechemistry that is highly effective in destroying all types of bacteria(including C difficile, MRSA, bacterial spores, and tuberculosis), fungi andviruses and is one of a small group of sporicidal agents that is safe and easyto use. Tristel plc operates with two divisions, Tristel Solutions and TristelTechnologies. Tristel Solutions focuses on infection control products for NHS and privatesector hospitals, primary care trusts, community hospitals, private practices,dental practices and veterinary establishments. The Company's products are usedon instruments, surfaces, and the skin in over 375 UK hospitals, representingsome 60 per cent of all UK NHS Acute & Private Hospitals. Tristel Technologies provides products for Legionella infection control inbuilding water systems and for contamination control in the food growing andfood processing industries. Tristel Technologies has approximately 200 customersin the government, municipal, industrial, healthcare and food sectors and more40 UK hospitals where its products are used for Legionella control. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Oct 20067:01 amRNSFinal Results
12th Oct 20067:01 amRNSNotice of Results
29th Aug 20067:01 amRNSAcquisition
9th Aug 200612:00 pmRNSDirector/PDMR Shareholding
9th Aug 20067:00 amRNSAcquisition update
16th Jun 20063:39 pmRNSDirector/PDMR Shareholding
6th Jun 20067:01 amRNSAcquisition update
26th May 20068:56 amRNSDirector/PDMR Shareholding
25th May 20068:21 amRNSDirector/PDMR Shareholding
24th May 200611:10 amRNSDirector/PDMR Shareholding
23rd May 20067:03 amRNSAcquisition & Trading Update
13th Feb 20067:01 amRNSInterim Results
6th Feb 200611:10 amRNSNotice of Results
23rd Dec 200512:22 pmRNSGrant of Options
15th Nov 200511:36 amRNSAGM Statement
7th Oct 20057:00 amRNSDirector/PDMR Shareholding
5th Oct 20053:29 pmRNSNotice of AGM
4th Oct 20055:18 pmRNSDividend payment date
3rd Oct 20057:00 amRNSFinal Results
19th Sep 20054:08 pmRNSNotice of Results
4th Jul 20057:00 amRNSGrant of Patent

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.